Lo Grasso Letizia, Maffioli Sonia, Sosio Margherita, Bibb Mervyn, Puglia Anna Maria, Alduina Rosa
Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Palermo, Italy.
Naicons Srl, Milan, Italy.
J Bacteriol. 2015 Aug 1;197(15):2536-44. doi: 10.1128/JB.00262-15. Epub 2015 May 18.
The actinomycete Nonomuraea sp. strain ATCC 39727 produces the glycopeptide A40926, the precursor of dalbavancin. Biosynthesis of A40926 is encoded by the dbv gene cluster, which contains 37 protein-coding sequences that participate in antibiotic biosynthesis, regulation, immunity, and export. In addition to the positive regulatory protein Dbv4, the A40926-biosynthetic gene cluster encodes two additional putative regulators, Dbv3 and Dbv6. Independent mutations in these genes, combined with bioassays and liquid chromatography-mass spectrometry (LC-MS) analyses, demonstrated that Dbv3 and Dbv4 are both required for antibiotic production, while inactivation of dbv6 had no effect. In addition, overexpression of dbv3 led to higher levels of A40926 production. Transcriptional and quantitative reverse transcription (RT)-PCR analyses showed that Dbv4 is essential for the transcription of two operons, dbv14-dbv8 and dbv30-dbv35, while Dbv3 positively controls the expression of four monocistronic transcription units (dbv4, dbv29, dbv36, and dbv37) and of six operons (dbv2-dbv1, dbv14-dbv8, dbv17-dbv15, dbv21-dbv20, dbv24-dbv28, and dbv30-dbv35). We propose a complex and coordinated model of regulation in which Dbv3 directly or indirectly activates transcription of dbv4 and controls biosynthesis of 4-hydroxyphenylglycine and the heptapeptide backbone, A40926 export, and some tailoring reactions (mannosylation and hexose oxidation), while Dbv4 directly regulates biosynthesis of 3,5-dihydroxyphenylglycine and other tailoring reactions, including the four cross-links, halogenation, glycosylation, and acylation.
This report expands knowledge of the regulatory mechanisms used to control the biosynthesis of the glycopeptide antibiotic A40926 in the actinomycete Nonomuraea sp. strain ATCC 39727. A40926 is the precursor of dalbavancin, approved for treatment of skin infections by Gram-positive bacteria. Therefore, understanding the regulation of its biosynthesis is also of industrial importance. So far, the regulatory mechanisms used to control two other similar glycopeptides (balhimycin and teicoplanin) have been elucidated, and beyond a common step, different clusters seem to have devised different strategies to control glycopeptide production. Thus, our work provides one more example of the pitfalls of deducing regulatory roles from bioinformatic analyses only, even when analyzing gene clusters directing the synthesis of structurally related compounds.
放线菌诺卡氏菌属菌株ATCC 39727产生糖肽A40926,即达巴万星的前体。A40926的生物合成由dbv基因簇编码,该基因簇包含37个参与抗生素生物合成、调控、免疫和输出的蛋白质编码序列。除了正向调节蛋白Dbv4外,A40926生物合成基因簇还编码另外两个推定的调节因子Dbv3和Dbv6。这些基因中的独立突变,结合生物测定和液相色谱 - 质谱(LC - MS)分析,表明Dbv3和Dbv4都是抗生素产生所必需的,而dbv6的失活没有影响。此外,dbv3的过表达导致A40926产量更高。转录和定量逆转录(RT)-PCR分析表明,Dbv4对于两个操纵子dbv14 - dbv8和dbv30 - dbv35的转录至关重要,而Dbv3正向控制四个单顺反子转录单元(dbv4、dbv29、dbv36和dbv37)以及六个操纵子(dbv2 - dbv1、dbv14 - dbv8、dbv17 - dbv15、dbv21 - dbv20、dbv24 - dbv28和dbv30 - dbv35)的表达。我们提出了一个复杂且协调的调控模型,其中Dbv3直接或间接激活dbv4的转录,并控制4 - 羟基苯甘氨酸和七肽骨架的生物合成、A40926的输出以及一些修饰反应(甘露糖基化和己糖氧化),而Dbv4直接调节3,5 - 二羟基苯甘氨酸的生物合成和其他修饰反应,包括四个交联、卤化、糖基化和酰化。
本报告扩展了对放线菌诺卡氏菌属菌株ATCC 39727中用于控制糖肽抗生素A40926生物合成的调控机制的认识。A40926是达巴万星的前体,已被批准用于治疗革兰氏阳性菌引起的皮肤感染。因此,了解其生物合成的调控在工业上也具有重要意义。到目前为止,用于控制另外两种类似糖肽(巴利霉素和替考拉宁)的调控机制已经阐明,除了一个共同步骤外,不同的基因簇似乎设计了不同的策略来控制糖肽的产生。因此,我们的工作提供了另一个例子,说明仅从生物信息学分析推断调控作用的陷阱,即使是在分析指导结构相关化合物合成的基因簇时。